CA19-9 as a Predictor of Worse Clinical Outcome in Medullary Thyroid Carcinoma | Zendy

Renata Carvalho Alencar | Zendy; Daniel Barretto Kendler | Zendy; Fernanda Accioly de Andrade | Zendy; C Nava | Zendy; Daniel Bulzico | Zendy; Cencita Cordeiro de Noronha Pessoa | Zendy; Rossana Corbo | Zendy; Fernanda Vaisman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

CA19-9 as a Predictor of Worse Clinical Outcome in Medullary Thyroid Carcinoma

Author(s) -

Renata Carvalho Alencar,

Daniel Barretto Kendler,

Fernanda Accioly de Andrade,

C Nava,

Daniel Bulzico,

Cencita Cordeiro de Noronha Pessoa,

Rossana Corbo,

Fernanda Vaisman

Publication year - 2019

Publication title -

european thyroid journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.23

H-Index - 10

eISSN - 2235-0802

pISSN - 2235-0640

DOI - 10.1159/000497201

Subject(s) - medicine , carcinoembryonic antigen , ca19 9 , calcitonin , thyroid carcinoma , tumor marker , medullary thyroid cancer , gastroenterology , medullary carcinoma , thyroid , oncology , cancer , pancreatic cancer

Medullary thyroid carcinoma (MTC) is a rare disease, and its classic tumor marker is calcitonin. However, recently, very aggressive cases have been reported to also secrete carbohydrate antigen 19-9 (CA19-9), and its role as a marker of worse prognosis has been questioned. The aim of this study was to analyze the relationship between CA19-9 serum levels and MTC outcomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research